Try our beta test site

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: November 1999
The purpose of this study is to see if it is safe and effective to add PMPA Prodrug (a new anti-HIV drug) to an anti-HIV drug combination taken by patients who have taken anti-HIV drugs in the past. Genetic response will be studied.

Condition Intervention Phase
HIV Infections
Drug: Tenofovir disoproxil fumarate
Phase 2

Study Type: Interventional
Study Design: Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Antiviral Activity of the Addition of PMPA Prodrug to Combination Antiretroviral Regimens in Treatment-Experienced HIV-Infected Patients

Resource links provided by NLM:

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 175
Detailed Description:
Prior to study entry patients are stratified according to HIV-1 RNA level, CD4 cell count, and number of antiretroviral drugs. PMPA Prodrug or placebo is added to current antiretroviral regimens, and is administered in one of three dosing regimens. Patients randomized to receive placebo are eligible to receive open-label PMPA Prodrug for the remainder of the 48-week study period after at least 24 weeks post randomization.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

You may be eligible for this study if you:

  • Are HIV-positive.
  • Have an HIV count of 400 - 50,000 copies/ml.
  • Are expected to live for at least 1 year.
  • Have been taking the same anti-HIV drug combination (made up of no more than 3 anti-HIV drugs) for at least 8 weeks prior to study entry.
  • Are at least 18 years old.
  • Agree to use effective methods of birth control during the study.

Exclusion Criteria

You will not be eligible for this study if you:

  • Have taken medications for certain infections within 15 days prior to study entry.
  • Have a history of cancer, except Kaposi's sarcoma (KS) or skin cancer.
  • Develop a new AIDS-related condition within 30 days of study entry.
  • Have certain serious medical conditions, including severe nausea, vomiting, or other stomach problems that make you unable to take medications by mouth.
  • Have received a vaccine within 30 days prior to study entry.
  • Have taken certain medications, including those that may affect your kidneys.
  • Abuse alcohol or drugs.
  • Are pregnant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002415

  Hide Study Locations
United States, Alabama
Univ of Alabama at Birmingham / 1917 Rsch Cln
Birmingham, Alabama, United States, 35294
United States, Arizona
McDowell Clinic
Phoenix, Arizona, United States, 85016
United States, California
East Bay AIDS Ctr
Berkeley, California, United States, 94705
Tower Infectious Disease Med Ctr
Los Angeles, California, United States, 90048
UCSD Treatment Ctr
San Diego, California, United States, 92103
San Francisco Veterans Adm Med Cntr
San Francisco, California, United States, 94121
Harbor UCLA Med Ctr
Torrance, California, United States, 90502
United States, Colorado
Univ of Colorado Health Sciences Ctr
Denver, Colorado, United States, 80262
United States, Florida
Hillsborough County Health Dept Special Care Ctr
Tampa, Florida, United States, 33605
United States, Georgia
AIDS Research Consortium of Atlanta Inc
Atlanta, Georgia, United States, 30308
Grady Mem Hosp
Atlanta, Georgia, United States, 30308
Private Practice / Thacker and Thompson
Atlanta, Georgia, United States, 30324
United States, Illinois
Northstar Med Clinic
Chicago, Illinois, United States, 60657
United States, Massachusetts
CRI New England
Brookline, Massachusetts, United States, 02445
United States, Minnesota
Univ of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New York
Beth Israel Med Ctr
New York, New York, United States, 10003
Cornell Clinical Trials Unit - Chelsea Clinic
New York, New York, United States, 10011
United States, Ohio
Univ Hosps of Cleveland
Cleveland, Ohio, United States, 44106
United States, Oregon
The Research and Education Group
Portland, Oregon, United States, 97210
United States, Pennsylvania
Hershey Med Ctr
Hershey, Pennsylvania, United States, 17033
Anderson Clinical Research
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
Roger Williams Med Ctr
Providence, Rhode Island, United States, 02908
United States, Texas
Amelia Ct Clinic
Dallas, Texas, United States, 75235
Thomas Street Clinic
Houston, Texas, United States, 77009
Sponsors and Collaborators
Gilead Sciences
  More Information

Miller MD, Margot NA, Schooley R, McGowan I. Baseline and week 48 final phenotypic analysis of HIV-1 from patients adding tenofovir disoproxil fumarate (TDF) therapy to background ART. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 441)
Schooley R, Myers R, Ruane R, Beall G, Lampiris H, McGowan I. A double-blind, placebo-controlled study of tenofovir disoproxil fumarate (TDF) for the treatment of HIV infection. 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sep (abstract no I302I) Identifier: NCT00002415     History of Changes
Other Study ID Numbers: 283B
Study First Received: November 2, 1999
Last Updated: June 23, 2005

Keywords provided by NIH AIDS Clinical Trials Information Service:
Drug Therapy, Combination
Anti-HIV Agents

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents processed this record on March 24, 2017